Efficacy and toxicity of stereotactic body radiotherapy for un-resectable stage III non-small cell lung cancer patients unfit for concurrent chemoradiation therapy: a retrospective study

Table 2 Univariate analysis of OS, PFS and LC for 213 patients with stage III NSCLC by SBRT combined with chemotherapy. *Others includes squamous cell carcinoma and NOS. OS, overall survival; PFS, progression-free survival; LC, local control; NSCLC, non-small cell lung cancer; SBRT, stereotactic body radiotherapy; KPS, karnofsky performance status; NOS, non-small cell lung cancer not otherwise specified; BED₁₀, biologically effective dose; PTV, planning target volume

Index	Median OS (month)	p value	Median PFS (month)	p value	Median LC (month)	p value
Age (yr)		0.417		0.406		0.698
≤ 70	37.4		16.0		58.8
>70	36.0		16.1		55.3
Gender		0.120		0.257		0.484
Male	35.3		15.6		56.2
Female	46.6		20.1		60.8
KPS		0.392		0.530		0.701
>80	39.6		16.9		58.3
≤ 80	36.0		15.6		56.4
History of smoking		0.045		0.056		0.292
Yes	33.1		14.3		55.0
No	41.8		19.0		60.4
Primary pulmonary diseases		0.722		0.261		0.207
Yes	36.1		16.7		60.8
No	37.0		15.8		54.6
TNM stage		0.166		0.006		0.014
IIIa	38.5		16.2		63.9
IIIb + IIIc	36.1		15.9		49.7
T stage		0.001		0.001		0.001
T1-2	44.2		18.6		65.4
T3-4	32.3		13.0		47.8
N stage		0.661		0.093		0.270
N0-2	34.0		15.6		60.4
N3	37.2		17.6		50.1
Pathologic pattern		0.001		0.071		0.037
Adenocarcinoma	44.6		18.6		62.2
Others*	30.7		14.2		51.4
Location of primary tumor		<0.001		0.004		<0.001
Central	26.9		13.9		45.9
Peripheral	42.3		17.8		64.5
BED₁₀ (Gy)		0.004		0.002		<0.001
≤ 85.0	31.6		13.1		26.5
>85.0	40.9		18.3		76.2
PTV(cm3)		<0.001		0.001		0.001
≤ 108.1	50.6		22.0		68.9
>108.1	30.7		12.9		21.6

ISSN: 1748-717X